Trial Profile

An observational, cohort study of ceftaroline in patients with spinal infections caused by gram-positive pathogens

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 27 Dec 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ceftaroline fosamil (Primary)
Indications Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections
Focus Adverse reactions; Therapeutic Use
Acronyms DISC

Most Recent Events

27 Dec 2016 New trial record
30 Oct 2016 Results of preliminary analysis (n=24) presented at the IDWeek 2016.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com